Clinical prognosis and gene expression profiles of prostate cancer patients with bone and lymphatic metastases

In this paper, we aimed to observe the prognosis and gene expression profiles of bone and lymphatic metastases. SEER*Stat software was used to collect prognosis analysis. Datasets of gene expression profiles were downloaded from the GEO database. GEO2R tool was used to analyze the data to identify the differentially expressed genes (DEGs). Functions of DEGs were annotated by KEGG. Protein interaction analysis and hub gene selection were performed using STRING database. The overall survival rate (OS) of Lymph node metastasis was better than that of bone metastases. In lymph node metastasis prostate cancer, the expression of ZWINT, DNMT3B and RAD54B was higher than that in bone metastasis prostate cancer; the expression of HBA2, MS4A4A, COLCE, CCL18, DCN, S100A4, ACP5, ARHGDIA, MEM204, GALR3, CTSZ, and EPHX1 was lower than that in bone metastasis prostate cancer. DEGs in bone metastasis prostate cancer were involved in various biological processes, such us enhancing the adhesion and chemotaxis, immune correlation and promoting malignant transformation of cancer cells. The data suggests that gene expression patterns of these two profiles are different. Bone metastasis may be poor prognosis and higher malignancy.